Company intelligence / Profile preview
Emergent BioSolutions
Gaithersburg, Maryland, United Statesemergentbiosolutions.com ↗
- Ownership
- Public · EBS
- Employees
- ~5000
- Development stage
- Commercial
01
Overview
Emergent BioSolutions has multiple commercial products including BioThrax (Anthrax Vaccine Absorbed), CYFENDUS (Anthrax Vaccine Absorbed, Adjuvanted), ACAM2000 (Smallpox and Mpox Vaccine), NARCAN Nasal Spray (naloxone HCl), and KLOXXADO (naloxone HCI) Nasal Spray 8 mg. The company has over 100 clinical trials and approximately 20 marketed drugs.
- Therapeutic areas
- NeurologyInfectious Diseases
- Modalities
- VaccinesTherapeuticsDrug-device combination products
- Industry
- Biotech
02
Drug pipeline
44 assets43 more assets in the full pipeline.
03
Partnerships
U.S. government (BARDA, NIAID)Ridgeback Therapeutics
04
Financials
- Market cap
- $299.9M
- Total revenue
- $742.9M
- Enterprise value
- $631.9M
Beyond the preview
Go deeper on Emergent BioSolutions.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Emergent BioSolutions.